Compare ADMA Biologics Inc (ADMA) vs Wix.Com Ltd (WIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Wix.Com Ltd — how do they compare? ADMA Biologics Inc trades at $9.16 (market cap $2.13B), while Wix.Com Ltd trades at $49 (market cap $2.11B). The key difference: ADMA Biologics Inc and Wix.Com Ltd are close in size by market cap. Which is the better fit depends on your goals.
| ADMA | WIX | |
|---|---|---|
Market Cap | $2.13B | $2.11B |
Sector | Health | Technology |
52-Week High | $20.38 | $184.24 |
52-Week Low | $7.60 | $40.43 |
Enterprise Value | $2.20B | $1.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
WIX trades at $50.36, up 2.05% today, amid mixed signals. The stock shows strong revenue growth, reaching $1.99B in 2025, but profitability remains inconsistent with a net margin of -1.97%. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Technical indicators are bullish overall, with RSI suggesting mild overbought conditions. Positive news includes partnerships with Elavon and Microsoft, though legal investigations pose headwinds.
Outlook: Analyst consensus is bullish with a $83.13 price target, but risks include legal scrutiny and volatile earnings. Investment opportunity lies in revenue growth and strategic partnerships, countered by profitability challenges and potential legal liabilities. Near-term performance hinges on Q2 2026 earnings and resolution of investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
